Combined treatment with an oncolytic adenovirus and antitumor activity of vincristine against retinoblastoma cells

International Journal of Molecular Sciences

Volumn 13, Issue 9, 2012, Pages 10736-10749

  Song, Xin ^a   Wang, Haibo ^a   Jia, Renbing ^a   Cun, Biyun ^a   Zhao, Xiaoping ^a   Zhou, Yixiong ^a   Xu, Xiaofang ^a   Qian, Guanxiang ^a   Ge, Shengfang ^a   Fan, Xianqun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Akt; Drug resistance; Oncolytic adenovirus; Retinoblastoma; Vincristine

Indexed keywords

ONCOLYTIC ADENOVIRUS; PROTEIN KINASE B; PROTEIN P53; RETINOBLASTOMA PROTEIN; VINCRISTINE; ANTINEOPLASTIC AGENT; ONCOLYTIC VIRUS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL COUNT; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENUCLEATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PROTEIN EXPRESSION; RETINOBLASTOMA; S PHASE CELL CYCLE CHECKPOINT; TUMOR CELL; WESTERN BLOTTING; ADENOVIRIDAE; CELL CYCLE; DRUG EFFECTS; METABOLISM; MULTIMODALITY CANCER THERAPY; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PHYSIOLOGY; RETINA; RETINAL NEOPLASMS; TUMOR CELL LINE; VIRUS REPLICATION;

ADENOVIRIDAE;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; HUMANS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROTO-ONCOGENE PROTEINS C-AKT; RETINA; RETINAL NEOPLASMS; RETINOBLASTOMA; VINCRISTINE; VIRUS REPLICATION;

EID: 84866893189     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms130910736     Document Type: Article

References (35)

1. Devesa, S.S. The incidence of retinoblastoma. Am. J. Ophthalmol. 1975, 80, 263-265.
2. Murphree, A.L.; Villablanca, J.G.; Deegan, W.F., III; Sato, J.K.; Malogolowkin, M.; Fisher, A.; Parker, R.; Reed, E.; Gomer, C.J. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch. Ophthalmol. 1996, 114, 1348-1356.
3. Abramson, D.H.; Frank, C.M.; Dunkel, I.J. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology 1999, 106, 1947-1950.
4. Chan, H.S.; Canton, M.D.; Gallie, B.L. Chemosensitivity and multidrug resistance to antineoplastic drugs in retinoblastoma cell lines. Anticancer Res. 1989, 9, 469-474.
5. Chan, H.S.; Thorner, P.S.; Haddad, G.; Gallie, B.L. Multidrug-resistant phenotype in retinoblastoma correlates with P-glycoprotein expression. Ophthalmology 1991, 98, 1425-1431.
6. Wilson, M.W.; Fraga, C.H.; Rodriguez-Galindo, C.; Hagedorn, N.; Leggas, M.L.; Stewart, C. Expression of the multi-drug resistance proteins and the pregnane X receptor in treated and untreated retinoblastoma. Curr. Eye Res. 2009, 34, 386-394.
7. Wilson, M.W.; Fraga, C.H.; Fuller, C.E.; Rodriguez-Galindo, C.; Mancini, J.; Hagedorn, N.; Leggas, M.L.; Stewart, C.F. Immunohistochemical detection of multidrug-resistant protein expression in retinoblastoma treated by primary enucleation. Investig. Ophthalmol. Vis. Sci. 2006, 47, 1269-1273.
8. Cun, B.; Song, X.; Jia, R.; Zhao, X.; Wang, H.; Ge, S.; Fan, X. Combination of oncolytic adenovirus and dacarbazine enhances antitumor ability against uveal melanoma cells via cell cycle block. Cancer Biol. Ther. 2012, 13, 77-84.
9. Song, X.; Zhou, Y.; Jia, R.; Xu, X.; Wang, H.; Hu, J.; Ge, S.; Fan, X. Inhibition of retinoblastoma in vitro and in vivo with conditionally replicating oncolytic adenovirus H101. Investig. Ophthalmol. Vis. Sci. 2010, 51, 2626-2635.
10. Zhang, H.; Wang, H.; Zhang, J.; Qian, G.; Niu, B.; Fan, X.; Lu, J.; Hoffman, A.R.; Hu, J.F.; Ge, S. Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors. Mol. Ther. J. Am. Soc. Gene Ther. 2009, 17, 57-64.
11. Gomez-Manzano, C.; Alonso, M.M.; Yung, W.K.; McCormick, F.; Curiel, D.T.; Lang, F.F.; Jiang, H.; Bekele, B.N.; Zhou, X.; Alemany, R. et al. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin. Cancer Res. 2006, 12, 556-562.
12. Fueyo, J.; Gomez-Manzano, C.; Alemany, R.; Lee, P.S.; McDonnell, T.J.; Mitlianga, P.; Shi, Y.X.; Levin, V.A.; Yung, W.K.; Kyritsis, A.P. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000, 19, 2-12.
13. Wang, X.; Su, C.; Cao, H.; Li, K.; Chen, J.; Jiang, L.; Zhang, Q.; Wu, X.; Jia, X.; Liu, Y. et al. A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers. Mol. Cancer Ther. 2008, 7, 1598-1603.
14. Friend, S.H.; Bernards, R.; Rogelj, S.; Weinberg, R.A.; Rapaport, J.M.; Albert, D.M.; Dryja, T.P. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986, 323, 643-646.
15. Laurie, N.A.; Donovan, S.L.; Shih, C.S.; Zhang, J.; Mills, N.; Fuller, C.; Teunisse, A.; Lam, S.; Ramos, Y.; Mohan, A.; et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006, 444, 61-66.
16. Laurie, N.A.; Shih, C.S.; Dyer, M.A. Targeting MDM2 and MDMX in retinoblastoma. Curr. Cancer Drug Targets 2007, 7, 689-695.
17. Marine, J.C.; Dyer, M.A.; Jochemsen, A.G. MDMX: From bench to bedside. J. Cell Sci. 2007, 120, 371-378.
18. Ottolino-Perry, K.; Diallo, J.S.; Lichty, B.D.; Bell, J.C.; McCart, J.A. Intelligent design: Combination therapy with oncolytic viruses. Mol. Ther. J. Am. Soc. Gene Ther. 2010, 18, 251-263.
19. Cheema, T.A.; Kanai, R.; Kim, G.W.; Wakimoto, H.; Passer, B.; Rabkin, S.D.; Martuza, R.L. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin. Cancer Res. 2011, 17, 7383-7393.
20. Hoffmann, D.; Bayer, W.; Wildner, O. Local and distant immune-mediated control of colon cancer growth with fusogenic membrane glycoproteins in combination with viral oncolysis. Hum. Gene Ther. 2007, 18, 435-450.
21. Cinatl, J., Jr.; Cinatl, J.; Michaelis, M.; Kabickova, H.; Kotchetkov, R.; Vogel, J.U.; Doerr, H.W.; Klingebiel, T.; Driever, P.H. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma. Cancer Res. 2003, 63, 1508-1514.
22. De Potter, P. Current treatment of retinoblastoma. Curr. Opin. Ophthalmol. 2002, 13, 331-336.
23. Balwierz, W.; Pietrys, D.; Romanowska-Dixon, B.; Kobylarz, J.; Pawinska-Wasikowska, K.; Moryl-Bujakowska, A. Results of combined chemotherapy and local ophtalmic therapy for intraocular retinoblastoma. Przegl. Lek. 2010, 67, 404-408.
24. Qian, J.; Xue, K.; Gao, Y.J.; Yuan, Y.F.; Shan, H.D.; Bi, Y.W. Clinical therapeutic efficiency of chemoreduction and local therapy for children with retinoblastoma (in chinese). Zhonghua Yanke Zazhi 2010, 46, 312-316.
25. Kim, H.; Lee, J.W.; Kang, H.J.; Park, H.J.; Kim, Y.Y.; Shin, H.Y.; Yu, Y.S.; Kim, I.H.; Ahn, H.S. Clinical results of chemotherapy based treatment in retinoblastoma patients: A single center experience. Cancer Res. Treat. 2008, 40, 164-171.
26. Shields, C.L.; Shields, J.A. Basic understanding of current classification and management of retinoblastoma. Curr. Opin. Ophthalmol. 2006, 17, 228-234.
27. Turaka, K.; Shields, C.L.; Meadows, A.T.; Leahey, A. Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma. Pediatr. Blood Cancer 2011, 59, 121-125.
28. Ji, X.; Zhang, J.; Cheng, L.; Wei, F.; Li, H.; Liu, X.; Chen, X.; Li, C.; Wang, Y.; Huang, Q. Oncolytic adenovirus delivering herpes simplex virus thymidine kinase suicide gene reduces the growth of human retinoblastoma in an in vivo mouse model. Exp. Eye Res. 2009, 89, 193-199.
29. Gallie, B.L.; Dunn, J.M.; Chan, H.S.; Hamel, P.A.; Phillips, R.A. The genetics of retinoblastoma. Relevance to the patient. Pediatr. Clin. North Am. 1991, 38, 299-315.
30. Abramson, D.H.; Schefler, A.C. Update on retinoblastoma. Retina 2004, 24, 828-848.
31. Nevins, J.R. E2F: A link between the Rb tumor suppressor protein and viral oncoproteins. Science 1992, 258, 424-429.
32. Hennessy, B.T.; Smith, D.L.; Ram, P.T.; Lu, Y.; Mills, G.B. Exploiting the PI3K/Akt pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005, 4, 988-1004.
33. Gu, P.; Su, Y.; Guo, S.; Teng, L.; Xu, Y.; Qi, J.; Gong, H.; Cai, Y. Over-expression of COX-2 induces human ovarian cancer cells (CAOV-3) viability, migration and proliferation in association with PI3-k/Akt activation. Cancer Investig. 2008, 26, 822-829.
34. Zhang, H.; Li, B.; Bai, S.W.; Wang, H.J. Constitutively active Akt contributes to vincristine resistance in human retinoblastoma cells. Cancer Investig. 2010, 28, 156-165.
35. Bernt, K.M.; Steinwaerder, D.S.; Ni, S.; Li, Z.Y.; Roffler, S.R.; Lieber, A. Enzyme-activated prodrug therapy enhances tumor-specific replication of adenovirus vectors. Cancer Res. 2002, 62, 6089-6098.